More articles about Cancer

The kit detects 29 mutations in exons 18, 19, 20, and 21, and has a limit of mutation detection at .1 percent in a background of wild-type DNA.

The scientists hope to incorporate the method, which can measure endogenous peptides at zeptomolar concentrations, in clinical trials starting next year.

The device allows researchers to track cancer growth for a longer period of time, enabling improved observations and analysis, according to the researchers.

The team used CRISPR to inactivate a gene in colon organoids, and found that a specific DNA repair defect underlies a mutational signature in some cancers.

The study, which looked at 41 breast cancer cell lines, suggests that such an approach could enable higher-throughput protein-protein interaction work.

Researchers identified unique ALK rearrangements in patients that lack previously known indicators of mesothelioma.

Tempus will provide molecular sequencing and data analysis for patients with metastatic or incurable cancer enrolled in a Cleveland Clinic study.

Swedish Cancer Institute has enlisted machine-learning technology vendor GNS Healthcare to model patient-specific breast cancer tumor data.

Enpicom will initially offer separate solutions on its ImmunoGenomiX platform for research and clinical applications in oncology but seeks to expand into other disease areas.

Researchers saw mismatch repair-related mutations in a significant subset of breast cancers, hinting at potential response to checkpoint blockade immunotherapy.

Genomic Health will gain exclusive worldwide rights to develop and sell an IVD version of its Oncotype DX breast cancer test on Biocartis' Idylla platform.

The firm will hold the intellectual property for its cell capture and analysis technology as QMUL files patents for recent findings using the Parsortix system.

The group is proposing women ages 30 to 65 be screened with cervical cytology every three years or receive testing for high-risk HPV every five years.

The company shared validation data this week that it said led the FDA to approve use of the test in a new prospective trial of Roche's Tecentriq in NSCLC.

The company said that it plans to use the funds to develop NGS assays in the oncology and precision medicine space, and expand its US commercial team.

Ambry will provide genetic testing in NorthShore’s Genomic Health Initiative in hopes of moving precision medicine into clinical practice.

Next year, the company will submit regulatory filings for the drug in two molecularly defined indications and a next-generation sequencing companion diagnostic. 

The companies will market Angle's Parsortix system for harvesting circulating tumor cells with Qiagen's liquid biopsy product portfolio.

Researchers from France's Gustave Roussy Institute designed EGFR mutation assays for the system, which they showed could be useful for testing in non-small cell lung cancer patients.

The test, miRpredX 31-3p, is a positive theranostic test that quantifies the expression of miR-31-3p in FFPE using RT-qPCR technology. 

Pages

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.